Absci Corporation (NASDAQ:ABSI) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET
Company Participants
Alex Khan – VP, Finance and IR
Sean McClain – Founder and Chief Executive Officer
Zach Jonasson – Chief Financial Officer and Chief Business Officer
Christian Stegmann – Senior Vice President of Drug Creation
Conference Call Participants
Arseniy Shabashvili – Guggenheim Securities
Brendan Smith – TD Cowen
Gil Blum – Needham & Company
George Farmer – Scotiabank
Debanjana Chatterjee – Jones
Li Chen – H.C. Wainwright
Operator
Thank you for standing by, and welcome to Absci’s First Quarter 2025 Business Update and Financial and Operating Results Conference Call. At this time all participants are in a listen-only-mode. After the speaker presentation there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the call over to Alex Khan, VP, Finance and Investor Relations. Please go ahead.
Alex Khan
Thank you. Earlier today, Absci released financial and operating results for the quarter ended March 31, 2025. If you haven’t received this news release or if you would like to be added to the company’s distribution list, please send an e-mail to investors@absaci.com. An archived webcast of this call will be available for replay on Absci’s Investor Relations website at investors.absci.com for at least 90 days after this call.
Joining me today are Sean McClain, Absci’s Founder and CEO; and Zach Jonasson, Chief Financial Officer and Chief Business Officer. Christian Stegmann, Absci’s SVP of Drug Creation, will also join for Q&A following prepared remarks.
Before we begin, I’d like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place
#Absci #Corporation #ABSI #Earnings #Call #Transcript